Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil

Página do item simplificado
dc.contributor.authorToniolo Neto, João [UNIFESP]
dc.contributor.authorAraujo, Gabriela Tannus Branco de [UNIFESP]
dc.contributor.authorGagliardi, Anna Maria Zaragoza [UNIFESP]
dc.contributor.authorPinho, Amanda
dc.contributor.authorDurand, Laure
dc.contributor.authorFonseca, Marcelo Cunio Machado [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionAxia Bio Consulting
dc.contributor.institutionSanofi Pasteur
dc.date.accessioned2016-01-24T14:17:15Z
dc.date.available2016-01-24T14:17:15Z
dc.date.issued2011-10-01
dc.description.abstractVaccination of adults aged 60 years and older against Streptococcus pneumonia is not recommended in Brazil. the 23-valent polysaccharide pneumococcal vaccine (PPV23) is only available for institutionalized persons or with underlying diseases despite the substantial medical and economic burden related to pneumococcal infections in adults over than 59 years. the study aimed at evaluating the cost effectiveness of implementing a large PP V program in this population.This analysis was performed using a static decision tree model. Demographic and epidemiological data were obtained from Brazilian official sources and international literature. Economic data were obtained from a study performed in 2007 in a public and a private hospital located in São Paulo. Vaccination was assumed to protect for 5 years with 60% effectiveness against bacteremic pneumococcal pneumonia (BPP) and 21% effectiveness against non bacteremic pneumococcal pneumonia (NBPP). Deterministic and sensitivity analyses were performed.The pneumococcal polysaccharide vaccination saved 5,218 life year gained (LYG). the vaccination program was found to be cost effective in the social security and public health care perspectives with a mean incremental cost-effectiveness ratio of R$10,887 and R$8,281 per LYG respectively. Results were sensitive to the vaccine effectiveness against NBPP, the incidence and case-fatality rate of NBPP. From a societal perspective, PPV23 program for adults 60 and older was found to be cost-saving.Pneumococcal polysaccharide vaccination is clinically and economically favored over the present vaccination strategy, in which persons aged over 59 years in São Paulo have not been vaccinated.en
dc.description.affiliationUniversidade Federal de São Paulo, São Paulo, Brazil
dc.description.affiliationAxia Bio Consulting, São Paulo, Brazil
dc.description.affiliationSanofi Pasteur, São Paulo, Brazil
dc.description.affiliationSanofi Pasteur, Lyon, France
dc.description.affiliationUnifespUniversidade Federal de São Paulo, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipsanofi pasteur
dc.format.extent1037-1047
dc.identifierhttps://dx.doi.org/10.4161/hv.7.10.15987
dc.identifier.citationHuman Vaccines. Austin: Landes Bioscience, v. 7, n. 10, p. 1037-1047, 2011.
dc.identifier.doi10.4161/hv.7.10.15987
dc.identifier.fileWOS000296564800016.pdf
dc.identifier.issn1554-8600
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/34081
dc.identifier.wosWOS:000296564800016
dc.language.isoeng
dc.publisherLandes Bioscience
dc.relation.ispartofHuman Vaccines
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPneumococcal polysaccharide vaccineen
dc.subjectCost-effectiveness analysisen
dc.subjectBrazilen
dc.subjectElderlyen
dc.titleCost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazilen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000296564800016.pdf
Tamanho:
1.49 MB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos